Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals IncfiledCriticalAlnylam Pharmaceuticals Inc
Publication of AR103676A1publicationCriticalpatent/AR103676A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Agentes de ARNi, por ejemplo, agentes de ARNi de cadena doble, dirigidos a un gen que contiene un dominio fosfolipasa tipo patatina 3 (PNPLA3) y métodos de uso de dichos agentes de ARNi para inhibir la expresión de un gen PNPLA3 y métodos de tratamiento de sujetos con una enfermedad de hígado de graso no alcohólico (NAFLD) y/o un trastorno asociado a PNPLA3.RNAi agents, for example, double-stranded RNAi agents, targeting a gene that contains a patatin 3 phospholipase domain (PNPLA3) and methods of using said RNAi agents to inhibit the expression of a PNPLA3 gene and treatment methods of subjects with a non-alcoholic fatty liver disease (NAFLD) and / or a disorder associated with PNPLA3.
ARP160100392A2015-02-132016-02-12
ARNi COMPOSITIONS CONTAINING A PATTERN TYPE 3 PHOSPHOLIPASE DOMAIN (PNPLA3) AND ITS METHODS OF USE
AR103676A1
(en)
COMPOSITIONS OF ARNi AGAINST FACTOR XII (HAGEMAN FACTOR) (F12), CALICREIN B, PLASMATIC (FLETCHER FACTOR) 1 (KLKB1), AND QUININOGEN 1 (KNG1) AND METHODS OF USE OF THE SAME